MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care

Stock Information for OptiNose Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About OptiNose Inc.

MediWound Reports New Clinical Data Demonstrating NexoBrid®'s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries
MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update
MediWound to Report Third Quarter 2025 Financial Results
MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia
MediWound's NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress
MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.